ASX:IBX

Stock Analysis Report

Executive Summary

Imagion Biosystems Limited provides tools to detect and eliminate cancer.

Snowflake

Fundamentals

Adequate balance sheet and overvalued.

Share Price & News

How has Imagion Biosystems's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IBX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

5.0%

IBX

4.9%

AU Medical Equipment

0.9%

AU Market


1 Year Return

-53.3%

IBX

46.9%

AU Medical Equipment

16.3%

AU Market

Return vs Industry: IBX underperformed the Australian Medical Equipment industry which returned 46.9% over the past year.

Return vs Market: IBX underperformed the Australian Market which returned 16.3% over the past year.


Shareholder returns

IBXIndustryMarket
7 Day5.0%4.9%0.9%
30 Day-41.7%5.0%1.4%
90 Day-57.1%13.4%6.0%
1 Year-53.3%-53.3%49.3%46.9%23.0%16.3%
3 Yearn/a69.5%62.0%41.6%22.3%
5 Yearn/a159.3%138.5%57.7%22.5%

Price Volatility Vs. Market

How volatile is Imagion Biosystems's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Imagion Biosystems undervalued compared to its fair value and its price relative to the market?

2.42x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IBX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate IBX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IBX is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: IBX is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IBX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IBX is good value based on its PB Ratio (2.4x) compared to the AU Medical Equipment industry average (4.9x).


Next Steps

Future Growth

How is Imagion Biosystems forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

21.2%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Imagion Biosystems has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Imagion Biosystems performed over the past 5 years?

-9.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IBX has a high level of non-cash earnings.

Growing Profit Margin: IBX's current net profit margins (-206.1%) are higher than last year (-2248%).


Past Earnings Growth Analysis

Earnings Trend: IBX is unprofitable, and losses have increased over the past 5 years at a rate of -9.3% per year.

Accelerating Growth: Unable to compare IBX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IBX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (29.5%).


Return on Equity

High ROE: IBX has a negative Return on Equity (-181.71%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Imagion Biosystems's financial position?


Financial Position Analysis

Short Term Liabilities: IBX's short term assets (A$3.4M) exceeds its short term liabilities (A$1.1M)

Long Term Liabilities: IBX's short term assets (3.4M) exceeds its long term liabilities (18.6K)


Debt to Equity History and Analysis

Debt Level: IBX is debt free.

Reducing Debt: IBX had no debt 5 years ago.


Balance Sheet

Inventory Level: IBX has a low level of unsold assets or inventory.

Debt Coverage by Assets: IBX's debt is covered by short term assets (assets are 4.9031056636912E+17x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IBX has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: IBX has less than a year of cash runway if free cash flow continues to reduce at historical rates of -15.3% each year


Next Steps

Dividend

What is Imagion Biosystems's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.4%markettop25%5.6%industryaverage1.5%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate IBX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate IBX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IBX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IBX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IBX's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

What is the CEO of Imagion Biosystems's salary, the management and board of directors tenure and is there insider trading?

1.6yrs

Average board tenure


CEO

Bob Proulx (61yo)

0yrs

Tenure

AU$958,038

Compensation

Mr. Robert Romeo Proulx, also known as Bob, has been the President and Chief Executive Officer at Imagion Biosystems, Inc. since January 12, 2015. Mr. Proulx's responsibilities include building Senior Scie ...


CEO Compensation Analysis

Compensation vs Market: Bob's total compensation ($USD652.53K) is above average for companies of similar size in the Australian market ($USD255.13K).

Compensation vs Earnings: Bob's compensation has increased whilst the company is unprofitable.


Board Age and Tenure

1.6yrs

Average Tenure

65yo

Average Age

Experienced Board: IBX's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellAU$1,007,38326 Jul 19
James Taylor
EntityIndividual
Shares15,098,818
Max PriceAU$0.067
SellAU$277,99525 Jul 19
Kemper Shaw
EntityIndividual
Shares5,000,000
Max PriceAU$0.056
BuyAU$999,99730 Jan 19
Kemper Shaw
EntityIndividual
Shares25,000,000
Max PriceAU$0.04

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 35.6%.


Management Team

  • Bob Proulx (61yo)

    Executive Chairman

    • Tenure: 0yrs
    • Compensation: AU$958.04k
  • Brian Conn

    Chief Financial Officer

    • Tenure: 0yrs
    • Compensation: AU$319.69k
  • Jovanka Naumoska

    Company Secretary & Non Executive Director

    • Tenure: 2.9yrs
    • Compensation: AU$23.82k
  • Marie Zhang

    Vice-President of Research & Pre- Clinical Dev

    • Tenure: 0.8yrs

Board Members

  • David Ludvigson (68yo)

    Non Executive Director

    • Tenure: 2.7yrs
    • Compensation: AU$23.82k
  • Bob Proulx (61yo)

    Executive Chairman

    • Tenure: 0yrs
    • Compensation: AU$958.04k
  • John Hazle

    Chairman of Scientific Advisory Board

    • Tenure: 1.3yrs
    • Compensation: AU$23.02k
  • Mike Harsh (65yo)

    Non-Executive Director

    • Tenure: 2.8yrs
    • Compensation: AU$23.82k
  • Robert Ivkov

    Member of Scientific Advisory Board

    • Tenure: 0.08yrs
  • Andrew Scott

    Member of Scientific Advisory Board

    • Tenure: 0.08yrs
  • Bronwyn Le Grice

    Non Executive Director

    • Tenure: 1.6yrs
    • Compensation: AU$10.86k
  • Jovanka Naumoska

    Company Secretary & Non Executive Director

    • Tenure: 2.9yrs
    • Compensation: AU$23.82k
  • Mark Van Asten

    Non Executive Director

    • Tenure: 2.9yrs
    • Compensation: AU$23.82k
  • Lisa Horvath

    Member of Scientific Advisory Board

    • Tenure: 0.08yrs

Company Information

Imagion Biosystems Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Imagion Biosystems Limited
  • Ticker: IBX
  • Exchange: ASX
  • Founded: 1996
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: AU$6.875m
  • Shares outstanding: 327.37m
  • Website: https://www.imagionbiosystems.com

Location

  • Imagion Biosystems Limited
  • 10355 Science Center Drive
  • Suite 210
  • San Diego
  • California
  • 92121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IBXNAASX (Australian Securities Exchange)NPV DFD 26/11/19(EX-RIGHTS)AUAUDNo data
IBXASX (Australian Securities Exchange)YesOrdinary SharesAUAUDJun 2017
IBXCHIA (Chi-X Australia)YesOrdinary SharesAUAUDJun 2017

Biography

Imagion Biosystems Limited provides tools to detect and eliminate cancer. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company was founded  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/17 10:42
End of Day Share Price2019/11/15 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.